Anti-fibrinolytic use for minimising perioperative allogeneic blood transfusion. Substantial update.

Field	Value	Language
dc.contributor.author	Henry DA	en
dc.contributor.author	Moxey AJ	en
dc.contributor.author	Carless PA	en
dc.contributor.author	O'Connell DL	en
dc.contributor.author	McClelland B	en
dc.contributor.author	Henderson KM	en
dc.contributor.author	Sly K	en
dc.contributor.author	Laupacis A	en
dc.contributor.author	Fergusson D	en
dc.date.issued	2001
dc.identifier.uri	https://hdl.handle.net/2123/30830
dc.publisher	Cochrane Database of Systematic Reviews	en
dc.rights	Other
dc.subject	6-Aminocaproic Acid	en
dc.subject	Erythrocyte Transfusion	en
dc.subject	Humans	en
dc.subject	New South Wales	en
dc.subject	pharmacology	en
dc.subject	Randomized Controlled Trials	en
dc.subject	Risk	en
dc.subject	surgery	en
dc.subject	therapeutic use	en
dc.subject	Tranexamic Acid	en
dc.subject	Transplantation,Homologous	en
dc.subject	Adult	en
dc.subject	trends	en
dc.subject	utilization	en
dc.subject	Wales	en
dc.subject	adverse effects	en
dc.subject	analysis	en
dc.subject	Antifibrinolytic Agents	en
dc.subject	Aprotinin	en
dc.subject	Australia	en
dc.subject	blood	en
dc.subject	Data Collection	en
dc.title	Anti-fibrinolytic use for minimising perioperative allogeneic blood transfusion. Substantial update.	en
dc.type	Article	en
dc.identifier.doi	10.1002/14651858.CD001886.pub3.
usyd.faculty	SeS faculties schools::Faculty of Medicine and Health	en

Associated file/s

There are no files associated with this item.